BioSpace News Archive

Results showed Alpine’s ICOSL vIgD-Fc fusion proteins demonstrated therapeutic efficacy, including suppressing an allogeneic immune response in vitro, improving survival, and reducing GvHD disease activity.

Amphivena plans to launch a Phase 1 clinical study in patients with MDS in early 2018.

The new RESONATE-2 data will be presented at the 59th ASH Annual Meeting and Exposition on Dec. 9 in Atlanta.

In 27 NSCLC patients who had received a median of two prior therapies, AM0010 in combination with either nivolumab or pembrolizumab induced a durable rate of tumor shrinkage of 41%.

The preclinical study showed ALPROLIX had a higher level of extravascular distribution and retention in certain joint areas when compared with conventional factor IX and a glycoPEGylated factor IX analog.

Two studies, one involving a novel drug and the other a gene therapy, could significantly improve the lives of people with the bleeding disorder hemophilia A.

Bristol-Myers Squibb Company announced data from the phase 2 CA180-372 study in pediatric patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) treated with Sprycel (dasatinib) added to a chemotherapy regimen modelled on a Berlin-Frankfurt-Munster high-risk backbone.

The studies employ unique therapeutic approaches and advanced engineering technologies such as the gene-editing platform CRISPR/Cas9, reflecting the fruits of many years of research dedication and innovation.

Tetra Bio-Pharma announced today that the Company has accepted the suggestion of Health Canada to change the order of its clinical trial application (CTA) review process.

The extended follow-up data demonstrated that patients treated with IMBRUVICA earlier (after first relapse) experienced the best clinical outcomes, in terms of both efficacy and tolerability.